Numerate combines its Drug Engineering process with our partners' world-class biology to fill the vacuum between basic research and clinical candidates.
Drug Engineering Partnerships
We apply our drug engineering technology to design and develop small molecule drugs in collaboration with a variety of partners. Together we can:
- Rapidly advance new therapeutic programs
- Redirect existing program to novel chemical spaces
- Design around existing IP and establish a more robust intellectual property estate
- Design backup series for lead programs
Given a high-level specification of the profile desired for a new drug candidate, we apply our process to engineer and (optionally) synthesize small numbers of compounds representing distinct chemical series. The engineered compounds are highly likely to meet the desired specification. Our partners verify their biological properties, and Numerate supports their optimization to the nomination of an IND candidate.
Numerate delivers leads and intellectual property worth aggressively pushing through a preclinical and clinical pipeline.
Advantage of Partnering with Us
Partnering with Numerate to engineer your leads gives you real advantages over in-house or out-sourced discovery.
Efficiency: Reduced time and cost
Our process greatly reduces the time and cost of generating validated lead series and valuable compound IP. Synthesis of the first compounds begins within three months.
Numerate has delivered compounds that fully meet the design specification in as little as 6 months with only two dozen compounds synthesized.
Risk-sharing: Outsource invention, not chemistry
We assume and mitigate the chemical design risk, and our upside is largely success-based. Partner agreements are structured to reward Numerate as engineered compounds prove to be successful through preclinical, clinical and market validation.
Value: Advance multiple series optimized against multiple goals
Numerate allows its partners to enter directly into the lead-optimization stage of a therapeutic program by delivering multiple series of compounds that are active, selective, patentable, drug-like and synthesizable. These multiple series make the program more robust to downstream preclinical attrition.
We enable out our partners to execute therapeutic programs faster, cheaper and with less risk.
